# C_2018214EN.01001101.xml

| 19.6.2018 | EN | Official Journal of the European Union | C 214/11 |
| --- | --- | --- | --- |

19.6.2018

EN

Official Journal of the European Union

C 214/11

---

Prior notification of a concentration

(Case M.8937 — Advent International/Zentiva)

Candidate case for simplified procedure

(Text with EEA relevance)

(2018/C 214/10)

1.

This notification concerns the following undertakings:

| — | Advent International Corporation (‘Advent’, USA), |
| --- | --- |

—

Advent International Corporation (‘Advent’, USA),

| — | Zentiva group of companies, including Zentiva Pharma GmbH (Germany), Winthrop Arzneimittel GmbH (Germany), Winthrop Pharmaceuticals UK Ltd (UK), Zentiva France (France), Zentiva Polska sp. z.o.o. (Poland), Zentiva S.A. (Romania), Zentiva, a.s. (Slovakia), Zentiva International, a.s. (Slovakia), Zentiva Group, a.s. (Czech Republic), Zentiva, k.s. (Czech Republic), Zentiva Portugal, Lda (Portugal), Zentiva Italia S.r.l. (Italy), Zentiva GmbH (Austria), Helvepharm AG (Switzerland) and Zentiva HU Kft (Hungary) (together ‘Zentiva’), currently controlled by Sanofi. |
| --- | --- |

—

Zentiva group of companies, including Zentiva Pharma GmbH (Germany), Winthrop Arzneimittel GmbH (Germany), Winthrop Pharmaceuticals UK Ltd (UK), Zentiva France (France), Zentiva Polska sp. z.o.o. (Poland), Zentiva S.A. (Romania), Zentiva, a.s. (Slovakia), Zentiva International, a.s. (Slovakia), Zentiva Group, a.s. (Czech Republic), Zentiva, k.s. (Czech Republic), Zentiva Portugal, Lda (Portugal), Zentiva Italia S.r.l. (Italy), Zentiva GmbH (Austria), Helvepharm AG (Switzerland) and Zentiva HU Kft (Hungary) (together ‘Zentiva’), currently controlled by Sanofi.

The proposed concentration consists of the acquisition of sole control by Advent of Zentiva within the meaning of Article 3(1)(b) of the Merger Regulation.

The concentration is accomplished by way of purchase of shares.

2.

—   for Advent: a global private equity investor, focused investments in several sectors, namely business and financial services; healthcare; industrial; retail, consumer and leisure; and technology, media and telecom.

—   for Zentiva: a pharmaceutical group focused on the development, manufacturing and marketing of generic pharmaceutical products primarily within Europe.

3.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.8937 — Advent International/Zentiva

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

| E-mail: COMP-MERGER-REGISTRY@ec.europa.eu |
| --- |
| Fax +32 229-64301 |
| Postal address: |
| European Commission |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

E-mail: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 229-64301

Postal address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

(2)  OJ C 366, 14.12.2013, p. 5.

2

---